Our Work in Dermatology

Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Atopic Dermatitis, Psoriasis

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in dermatology and those who are close to them.

RECENT PUBLICATIONS

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics—Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya – June 12, 2018
>VIEW ARTICLE

Bolstered Skin Clearance Allows for Ample First-Line Use of Biologics with Alternate Mechanisms of Action for the Treatment of Psoriasis – June 28, 2018
>VIEW ARTICLE

Sanofi/Regeneron’s Dupixent, the Darling of Atopic Dermatitis – May 3, 2018
>VIEW ARTICLE

Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis Management – March 8, 2018
>VIEW ARTICLE

UPCOMING CONFERENCES

Fall Clinical Dermatology Conference
>LEARN MORE